UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    25

    Press Release: UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

    • NAYZILAM will be available in retail pharmacies on December 2, 2019
    • Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*

    Read More Share:linkedin| twitter| email

    Nov

    15

    Press Release: Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study

    • The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints1
    • UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020

    Read More Share:linkedin| twitter| email

    Nov

    08

    Press Release: UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

    UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

    Read More Share:linkedin| twitter| email

    Nov

    06

    What You See Is What You Get

    UCB's Denelle Waynick, VP, Legal Affairs (U.S.), U.S. General Counsel and Global Head, Enterprise Risk Management, leads by example by being true to herself to encourage others to do so too. Read more from Denelle on why by being authentic to yourself, you become stronger as an individual, leader, and employee. Read the full article on LinkedIn.

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)